Wiley
1080-563X
1527-3458
Cơ quản chủ quản: N/A
Lĩnh vực:
Các bài báo tiêu biểu
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Tập 12 Số 1 - Trang 21-38 - 2006
Ethosuximide: From Bench to BedsideABSTRACT Ethosuximide, 2‐ethyl‐2‐methylsuccinimide, has been used extensively for “petit mal” seizures and it is a valuable agent in studies of absence epilepsy. In the treatment of epilepsy, ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy. Com... ...
Tập 13 Số 2 - Trang 224-239 - 2007
Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant DrugABSTRACT The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information pr... ...
Tập 13 Số 1 - Trang 57-78 - 2007
Mildronate: An Antiischemic Drug for Neurological IndicationsABSTRACT Mildronate (3‐(2,2,2‐trimethylhydrazinium)propionate; MET‐88; meldonium, quaterine) is an antiischemic drug developed at the Latvian Institute of Organic Synthesis. Mildronate was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid β‐oxidation in ischemic tissues and to block this high... ...
Tập 11 Số 2 - Trang 151-168 - 2005
Glatiramer Acetate in Multiple Sclerosis: A ReviewABSTRACT Multiple sclerosis (MS) is considered to be primarily an inflammatory autoimmune disease. Over the last 5 years, our view of the pathogenesis of MS has evolved considerably. The axonal damage was recognized as an early event in the disease process and as an important determinant of long‐term disability. Therefore, the antiinflammatory and neuroprotective st... ...
Tập 13 Số 2 - Trang 178-191 - 2007
MDL 100,907: A Selective 5‐HT2A Receptor Antagonist for the Treatment of Schizophrenia
Tập 3 Số 1 - Trang 49-67 - 1997